logo
Plus   Neg
Share
Email

Did You Invest In Galapagos?

galapagos-july16-lt.jpg

Shares of Galapagos NV (GLPG), which touched an all-time high of $174.63 in intraday trading on Monday, have gained 90 percent year-to-date. GLPG was trading around $55 when we alerted our premium subscribers to this stock on July 17, 2015.

Galapagos is a clinical-stage biotechnology company developing novel medicines for inflammation, fibrosis and other indications.

The Company's lead drug candidate is Filgotinib, which is under phase III programs in rheumatoid arthritis, Crohn's disease and ulcerative colitis as well as phase II studies in small bowel Crohn's disease, fistulizing Crohn's disease, Sjögren's syndrome, ankylosing spondylitis, psoriatic arthritis, cutaneous lupus erythematosus (CLE), lupus membranous nephropathy and uveitis.

Galapagos is partnered with Gilead Sciences Inc. (GILD) for the development and commercialization of Filgotinib. The partnership between the two companies for Filgotinib was signed in 2015.

On July 14, 2019, Galapagos announced a 10-year global research and development collaboration with Gilead, wherein Gilead has agreed to make $3.95 billion upfront payment and $1.1 billion equity investment.

The new agreement gives Gilead access to Galapagos portfolio of compounds, including six molecules currently in clinical trials, more than 20 preclinical programs and a proven drug discovery platform.

Galapagos and Gilead plan to seek regulatory approval for Filgotinib in rheumatoid arthritis in the United States and Europe before the end of this year.

Also in the pipeline are:

-- GLPG1690, currently in phase III development for idiopathic pulmonary disease, dubbed ISABELA.
-- GLPG1205, which is under a phase II trial in patients with idiopathic pulmonary disease, known as PINTA.
-- GLPG1972/S201086, which is under a phase II trial in patients with knee osteoarthritis, dubbed ROCCELLA. This compound is being developed by Galapagos in collaboration with France-based Servier. Results from the trial are expected to be reported next year.
-- MOR106, under a phase II trial in patients with moderate-to-severe atopic dermatitis, known as IGUANA, and another phase II study in patients with moderate to severe atopic dermatitis, dubbed GECKO.

MOR106 was developed through a strategic discovery and co-development alliance between Galapagos and MorphoSys (MOR) that was signed in 2008. Last July, Novartis licensed MOR106 from Galapagos and MorphoSys in a deal valued at $1 billion.

The Company ended the first quarter of 2019 (Mar.30, 2019) with cash and cash equivalents of 1.2 billion euros.

GLPG has traded in a range of $85.00 to $174.63 in the last year.

Related Reading

Countdown's Begun…

For comments and feedback contact: editorial@rttnews.com

Business News

Follow RTT
>